Anatomic and Visual Acuity Outcomes Following Thermal Laser Photocoagulation or Photodynamic Therapy for Symptomatic Circumscribed Choroidal Hemangioma With Associated Serous Retinal Detachment

2004 ◽  
Vol 35 (4) ◽  
pp. 281-291 ◽  
Author(s):  
Ingrid U Scott ◽  
Jason Gorscak ◽  
J Donald M Gass ◽  
William J Feuer ◽  
Timothy G Murray
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Retinal Detachment ◽  
Laser Photocoagulation ◽  
Serous Retinal Detachment ◽  
Choroidal Hemangioma

scholarly journals Photodynamic therapy of subfoveal choroidal neovascularization

2007 ◽  
Vol 135 (11-12) ◽  
pp. 629-634
Author(s):  
Ana Georgijevic ◽  
Zoran Tomic
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Blood Vessels ◽  
Choroidal Neovascularization ◽  
Retinal Pigment ◽  
Photochemical Reactions ◽  
Pathologic Myopia ◽  
Target Tissue ◽  
Choroidal Hemangioma

Introduction Photodynamic therapy (PDT) is a method of treatment of choroidal neovascularization (CNV) with a diode laser used after intravenously administered verteporfin. Verteporfin is a light-activated drug initiating photochemical reactions in the target tissue. This leads to the selective occlusion of blood vessels in the CNV with no damage of photoreceptors, retinal pigment epithelium and retinal blood vessels. Objective To show the results of the treatment of predominantly classic subfoveal CNV with PDT with verteporfin used for the first time in our country. Method From 2003 to 2005, we treated 15 eyes in 15 patients using PDT and verteporfin, because of predominantly classic subfoveal CNV. If macular oedema was present as proved by fluorescein angiography, triamcinolone was administered intravitreally after PDT. Average follow-up period was 7 months (3 months to 2 years). Study design: retrospective, noncomparative, consecutive case series. Results Two thirds of patients had CNV due to AMD, while in others it was caused by pathologic myopia, chorioretinitis, angioid streaks, choroidal hemangioma, except for one patient who had idiopathic CNV. Visual acuity was stabile in 60% (9/15) of patients, of whom in 60% (6/10) of patients with AMD, as well as in patients with pathologic myopia, idiopathic CNV and choroidal hemangioma. Retreatment with PDT was indicated in 40% (6/15) and in 50% (5/10) of patients with AMD, mostly 4-6 months after first PDT, but was done only in one patient (economic reasons). In two patients with AMD, triamcinolone was administered intravitreally for 2-4 months, which resulted in the stabilization of visual acuity. Conclusion Visual acuity was stabile in 60% of all treated patients with predominantly classic subfoveal CNV after only one application of PDT with verteporfin during the average follow-up of 7 months (3 months to 2 years). Retreatment was indicated in 40% of the treated patients, and in 50% of patients with AMD. As confirmed, intravitreal administration of triamcinolone after PDT could stabilize visual acuity. Side effects were not noticed.

SPONTANEOUS REGRESSION OF SEROUS RETINAL DETACHMENT ASSOCIATED WITH CIRCUMSCRIBED CHOROIDAL HEMANGIOMA AFTER CHILDBIRTH

2017 ◽  
Vol 11 (1) ◽  
pp. 7-11 ◽  
Author(s):  
Isil Sayman Muslubas ◽  
Serra Arf ◽  
Mumin Hocaoglu ◽  
Hakan Ozdemir ◽  
Murat Karacorlu
Keyword(s):  
Retinal Detachment ◽  
Spontaneous Regression ◽  
Serous Retinal Detachment ◽  
Choroidal Hemangioma

scholarly journals Unilateral Vogt-Koyanagi-Harada Disease: A Clinical Case Report

2015 ◽  
Vol 6 (3) ◽  
pp. 361-365 ◽  
Author(s):  
Arminda Neves ◽  
Ana Cardoso ◽  
Mariana Almeida ◽  
Joana Campos ◽  
António Campos ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Case Report ◽  
Retinal Detachment ◽  
Serous Retinal Detachment ◽  
Subretinal Fluid ◽  
Posterior Pole ◽  
Exudative Retinal Detachment ◽  
The Right ◽  
Clinical Records ◽  
Vkh Disease

Purpose: To report a case of a 20-year-old female with decreased visual acuity (VA) in the left eye (LE). Methods: This is a retrospective and descriptive case report based on data from clinical records, patient observation and analysis of diagnostic tests. Results: A 20-year-old female presented with decreased VA in the LE for 3 days. Best-corrected visual acuity (BCVA) was 20/20 in the right eye (RE) and 20/40 in the LE. Pupillary function, intraocular pressure, results of external segment examinations and slit-lamp biomicroscopy were normal, bilaterally. RE fundoscopy was normal, and in the LE it revealed papillitis and posterior pole exudative retinal detachment. Optical coherence tomography (OCT) confirmed the macular serous retinal detachment and showed thickening of the posterior choroid also revealed by orbital ultrasound and magnetic resonance imaging (MRI). Fluorescein angiography showed angiographic features typical of Vogt-Koyanagi-Harada (VKH) disease: disseminated spotted choroidal hyperfluorescence and choroidal multifocal hypofluorescence, multifocal profuse leakage in the retina with pooling, serous retinal detachment and optic disc hyperfluorescence. Serological testing for the diagnosis of infectious pathologies was negative, and the review of systems was normal. The patient received systemic steroids and cyclosporine. LE BCVA improved up to 20/20 at 18 months after the diagnosis, with complete reabsorption of subretinal fluid and normal retinal and choroidal thickness by OCT. Conclusion: Despite the unilateral involvement, the clinical and angiographic features were typical of VKH disease, and ophthalmologists should be aware to recognize this rare clinical variant of the disease.

scholarly journals Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy

2021 ◽  
Vol 10 (10) ◽  
pp. 2168
Author(s):  
Koji Tanaka ◽  
Ryusaburo Mori ◽  
Yu Wakatsuki ◽  
Hajime Onoe ◽  
Akiyuki Kawamura ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Choroidal Thickness ◽  
Retinal Thickness ◽  
Serous Retinal Detachment ◽  
Additional Treatment ◽  
Conventional Dose ◽  
Anti Vegf ◽  
Pachychoroid Neovasculopathy ◽  
One Year

Pachychoroid neovasculopathy (PNV) is treated with antivascular endothelial growth factor (VEGF) injection and photodynamic therapy (PDT), but no curative treatment has yet been established. We aimed to clarify the treatment results of a reduced dose of PDT for PNV. The subjects were 27 eyes of 27 patients (male:female = 20:7, mean age 58.9 years). PDT, at 2/3 of the conventional dose (2/3PDT), was administered once. The patients were then observed for one year. Eyes with polypoidal choroidal vasculopathy (PCV) were excluded. We investigated the associations among the central retinal thickness, choroidal thickness, and visual acuity changes before treatment and one, three, six and 12 months after PDT. When serous retinal detachment was increased or unchanged or new hemorrhages were observed, as compared with pretreatment findings, intravitreal injection of an anti-VEGF agent was performed. Visual acuity was significantly improved, as compared to before treatment, at three, six, and 12 months after 2/3PDT. Foveal retinal thickness was significantly decreased after versus before treatment in the 2/3PDT group (p < 0.001). Foveal choroidal thickness was also significantly reduced in the 2/3PDT group (p = 0.001). Additional intravitreal anti-VEGF agent injections were administered to three patients (11%), while 24 (89%) required no additional treatment during the one-year follow-up period. For PNV without polyps, 2/3PDT appears to be effective.

Sign in / Sign up

Export Citation Format

Share Document